Benek Ondrej, Musilek Kamil, Horova Anna, Dohnal Vlastimil, Dolezal Rafael, Kuca Kamil
University Hospital, Sokolska 581, 500 05 Hradec Kralove, Czech Republic.
Med Chem. 2014;11(1):21-9. doi: 10.2174/1573406410666140428153110.
This paper describes preparation and in vitro evaluation of 19 compounds related to the selective experimental cholinesterase inhibitor BW284c51. The novel compounds were prepared as fragments of parent molecule BW284c51 and evaluated on the model of human recombinant acetylcholinesterase and human plasmatic butyrylcholinesterase. The IC₅₀ values of the prepared compounds were compared to the parent molecule BW284c51. None of the compounds was superior to the parent drug, but two BW284c51 fragments showed promising hAChE inhibition in µM scale and improved selectivity. These two fragments were further subjected to the molecular modelling study and their enzyme interactions were rationalized. The structure-activity relationship of the prepared series was stated.
本文描述了与选择性实验性胆碱酯酶抑制剂BW284c51相关的19种化合物的制备及体外评估。这些新型化合物是作为母体分子BW284c51的片段制备的,并在人重组乙酰胆碱酯酶和人血浆丁酰胆碱酯酶模型上进行了评估。将制备的化合物的IC₅₀值与母体分子BW284c51进行了比较。没有一种化合物优于母体药物,但有两个BW284c51片段在微摩尔范围内显示出有前景的人乙酰胆碱酯酶抑制作用且选择性有所提高。对这两个片段进一步进行了分子模拟研究,并对它们与酶的相互作用进行了合理化分析。阐述了所制备系列化合物的构效关系。